ASH 2021

Although rare, there are cases in which classic Hodgkin lymphoma (CHL) and follicular lymphoma (FL) occur simultaneously at the same site. Known as composite classic Hodgkin lymphoma and follicular lymphoma (CHLFL), this condition is rare and not well understood. This article, published in the American Journal of Clinical Pathology, examined two case studies that showed...

A retrospective analysis of patients with classic Hodgkin lymphoma (cHL) treated with PD-1 inhibitors will be presented at the 2021 ASH Annual Meeting & Exposition. This study, published in Blood, sought to determine the safety and efficacy of the COVID-19 vaccine for these patients. Specifically, with regard to safety, the study looked at the frequency of...

A retrospective analysis of overall survival for patients with Hodgkin’s Lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), and primary central nervous system lymphoma (PCNS) will be presented at the 2021 ASH Annual Meeting & Exposition. This study, published in Blood, is the first large-scale population analysis on a specific state (Texas) to have examined the...

The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the election of three new members to its Executive Committee for terms beginning after the 2021 ASH Annual Meeting, December 11-14 in Atlanta, Georgia. Mohandas Narla, DSc, will serve a one-year term as...

Alemtuzumab is a monoclonal antibody that targets cell surface antigen CD52 on lymphocytes. It has been used to treat hematologic malignancies and has been incorporated into hematopoietic stem cell transplant (HSCT) conditioning regimens. However, few studies have evaluated the pharmacology of alemtuzumab in adults with sickle cell disease (SCD).   This study, published in Pharmacotherapy: The Journal...

An article published in Blood Advances reviewed past and ongoing clinical trials of adoptive immunotherapy for patients with classic Hodgkin lymphoma (cHL). The article also examined current challenges and strategies specific to improving the development of CAR T-cell therapy for cHL in general and relapsed or refractory cHL in particular.  The authors gathered data from eight past...

Many researchers have observed a disparity in overall survival between non-Hispanic Black Americans and non-Hispanic white Americans with multiple myeloma. However, the clinical characteristics and overall survival of Hispanic Americans with the disease remain unknown. This analysis aimed to characterize multiple myeloma in Hispanic Americans. A total of 939 patients were analyzed, with all patients...

Dr Lee Greenberg of the Lymphoma and Leukemia Society discuses health disparities among Black patients as it relates to blood cancers.

Multiple myeloma treatment has improved significantly in recent years. However, mortality early in the course of the disease is still common. This study focuses on discovering trends in early mortality. The researchers sought to better understand demographic and socioeconomic factors associated with early mortality, which can then be used to better target resources for those...